The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...
Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.
The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
Genethon has licensed to AskBio a component of a preclinical gene therapy approach for treating Pompe disease.
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
The firm expects a first readout from an investigator-initiated trial of an in vivo CAR T-cell therapy in the second half of this year.
The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback